Stay updated with breaking news from Treating Fields. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society
Novocure today announced 27 presentations on Tumor Treating Fields will be delivered at the American Association for Cancer Research Annual Meeting 2023, to be held April 14 to 19 in Orlando,... | April 14, 2023
Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer
Final data from the METIS study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating
Optune is now available as a treatment for newly diagnosed glioblastoma patients in France Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide